PR Newswire·Nov 14, 2026, 12:01 PM ET

Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale

LLY

Eli Lilly presented new data on its cardiometabolic portfolio at ObesityWeek 2026 in Washington, D.C., from November 14 to 17, 2026.
Phase 2 results for EloraTZP, an investigational combination of eloralintide & tirzepatide, showed up to 54.1 lbs (23.3%) weight loss & up to 2.9% A1C reduction in adults with obesity & type 2 diabetes.
Up to 60% of participants on EloraTZP no longer met BMI criteria for obesity, while up to 77% achieved normal blood sugar levels.
Retatrutide, an investigational triple agonist, reduced obstructive sleep apnea severity by up to 60.6% in the TRIUMPH-1 study & by 48.1% in TRIUMPH-2 over 80 weeks.
Retatrutide reduced knee osteoarthritis pain by up to 73.1% in TRIUMPH-1 & by 75.8% in TRIUMPH-4 over 68 to 80 weeks.
Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity over 72 weeks in the SURMOUNT-ADOLESCENTS study.
Real-world evidence from the FOUNDERS survey indicated 96-98% of Foundayo users found the once-daily oral medication simple & easy to use.
Eloralintide participants reported reductions in food cravings (74%), food noise (52%), & alcohol consumption (41%) in Phase 2 exit interviews.
Zepbound is FDA-approved for weight management in adults with obesity or overweight with weight-related conditions, & for treating moderate-to-severe obstructive sleep apnea in adults with obesity.
Foundayo is an FDA-approved once-daily oral GLP-1 receptor agonist for weight management, taken without food or water restrictions.
Both Zepbound & Foundayo carry warnings regarding thyroid tumors, pancreatitis, gallbladder problems, dehydration, kidney issues, & severe allergic reactions.
Retatrutide & eloralintide remain investigational molecules not yet approved for legal sale or marketing for human use.

Company: Eli Lilly and Company
Keywords: Eli Lilly and Company